Keywords: novartis, phase, iii, zelmac, data, treatment, irritable

Novartis' Phase III Zelmac data

Article | 27 October 1999

Print This

Novartis' treatment for irritable bowel syndrome Zelmac (tegaserod)has been shown to significantly reduce the key symptoms of IBS and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in